Predict your next investment

Bank
nrwbank.de

See what CB Insights has to offer

Investments

72

Portfolio Exits

11

Funds

12

About NRW.Bank

North Rhine-Westphalia Bank is a financial group supporting investment and development in the NRW state of Germany.

NRW.Bank Headquarters Location

Kavalleriestr. 22

Dusseldorf, D-40213,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest NRW.Bank News

Emergence Therapeutics Secures €87M in Series A Financing

Dec 14, 2021

Emergence Therapeutics AG , a Duisburg, Germany-based biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers, closed an €87m series A financing round. The round was led by Pontifax Venture Capital and includes RA Capital Management, OrbiMed Advisors, Surveyor Capital (a Citadel company) and Hadean Ventures as new investors as well as existing investors Kurma Partners, NRW.BANK, High-Tech Gründerfonds, Gründerfonds Ruhr and Bpifrance through its InnoBio 2 fund. Management also participated in the round. Proceeds from this funding round will be used to advance the company’s antibody drug conjugate (ADC) targeting Nectin-4 to clinical proof-of-concept as well as the development of additional ADC programs. Led by Jack Elands, CEO, Emergence is advancing ETx-22, a next-generation Nectin-4 ADC which has been optimized to increase efficacy and minimize toxicity. ETx-22 has shown to be selective for tumor-expressed Nectin-4 and has tumor-specific deconjugation resulting in reduced toxicity. ETx-22 will initially be developed for bladder and triple negative breast cancer as well as malignancies with medium and low nectin-4 expression levels, including ovarian, head and neck and lung cancer. Proceeds from the financing will also support the development of a pipeline of further ADC candidates. As part of the financing round, the Company announced the appointment of the following members to the Supervisory Board: Irina Staatz-Granzer (independent member, designated Chairperson) Roy Amariglio (OrbiMed Advisors) Matthew Hammond (RA Capital Management) Olivier Martinez (Bpifrance) Anke Caßing (High-Tech Gründerfonds)

NRW.Bank Investments

72 Investments

NRW.Bank has made 72 investments. Their latest investment was in DropFriends as part of their Seed on July 7, 2022.

CBI Logo

NRW.Bank Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/7/2022

Seed

DropFriends

Yes

1

2/16/2022

Series B - III

CryoTherapeutics

No

3

1/19/2022

Unattributed

everwave

Yes

1

12/7/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/11/2021

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

7/7/2022

2/16/2022

1/19/2022

12/7/2021

2/11/2021

Round

Seed

Series B - III

Unattributed

Series A

Seed VC

Company

DropFriends

CryoTherapeutics

everwave

Subscribe to see more

Subscribe to see more

Amount

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

3

1

10

10

NRW.Bank Portfolio Exits

11 Portfolio Exits

NRW.Bank has 11 portfolio exits. Their latest portfolio exit was phenox on April 21, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/21/2022

Acquired

$99M

4

12/23/2021

Acquired

$99M

5

10/4/2021

Acquired

$99M

2

10/29/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/16/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/21/2022

12/23/2021

10/4/2021

10/29/2020

7/16/2020

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

5

2

10

10

NRW.Bank Fund History

12 Fund Histories

NRW.Bank has 12 funds, including Seed Fund III Aachen.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/12/2018

Seed Fund III Aachen

$25M

1

12/31/2013

NRW.BANK.Seed Fonds Zwei GmbH & Co. KG

Early-Stage Venture Capital

Closed

1

12/31/2011

NRW.BANK.Venture Fonds Zwei GmbH & Co. KG

Early-Stage Venture Capital

Closed

$107.82M

1

12/31/2009

NRW.BANK.Kreativwirtschaftsfonds GmbH & Co. KG

Subscribe to see more

Subscribe to see more

$99M

10

1/31/2007

Seed-Fonds fuer die Region Aachen

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/12/2018

12/31/2013

12/31/2011

12/31/2009

1/31/2007

Fund

Seed Fund III Aachen

NRW.BANK.Seed Fonds Zwei GmbH & Co. KG

NRW.BANK.Venture Fonds Zwei GmbH & Co. KG

NRW.BANK.Kreativwirtschaftsfonds GmbH & Co. KG

Seed-Fonds fuer die Region Aachen

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$25M

$107.82M

$99M

$99M

Sources

1

1

1

10

10

NRW.Bank Team

2 Team Members

NRW.Bank has 2 team members, including current Managing Director, Claas Heise.

Name

Work History

Title

Status

Claas Heise

DTSI

Managing Director

Current

Dietmar P Binkowska

Chief Executive Officer

Former

Name

Claas Heise

Dietmar P Binkowska

Work History

DTSI

Title

Managing Director

Chief Executive Officer

Status

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.